Igho-Osagie: Prevalence of Potential Drug-Drug Interactions with Ritonavir-Containing COVID-19 therapy in the United States: An Analysis of the National Health and Nutrition Examination Survey [Paxlovid]

Prevalence of Potential Drug-Drug Interactions with Ritonavir-Containing COVID-19 therapy in the United States: An Analysis of the National Health and Nutrition Examination Survey

Igho-Osagie et al., Clinical Therapeutics, doi:10.1016/j.clinthera.2023.03.012

Igho-Osagie et al., Prevalence of Potential Drug-Drug Interactions with Ritonavir-Containing COVID-19 therapy in the United.., Clinical Therapeutics, doi:10.1016/j.clinthera.2023.03.012

Mar 2023 Source PDF

Twitter
Facebook

All Studies Meta

Analysis of 15,685 adults in the USA estimating that 29.3% of the population risk a major or contraindicated drug interaction with paxlovid, which may increase significantly for patients over 60 or with several comorbidities that also increase COVID-19 risk.

Important missing comments or errors? Let us know.

Igho-Osagie et al., 23 Mar 2023, USA, peer-reviewed, 6 authors.

Contact: kaylen.brzozowski@trinetx.com.

All Studies All Outcomes Submit Updates or Corrections

This Paper Paxlovid All

Prevalence of Potential Drug-Drug Interactions with Ritonavir-Containing COVID-19 therapy in the United States: An Analysis of the National Health and Nutrition Examination Survey

Ebuwa Igho-Osagie, Kaylen Brzozowski, Harry Jin, Jeffrey Brown, Marissa Grifasi Williams, Amy Puenpatom

Clinical Therapeutics, doi:10.1016/j.clinthera.2023.03.012

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

suspected major or contraindicated pDDIs (n, %) Number of CYP3A4-mediated medications with suspected major or contraindicated pDDIs used in past 30-days (mean, SD or SE)

References

Ahrenfeldt, Nielsen, Möller, Christensen, Lindahl-Jacobsen, Burden and prevalence of risk factors for severe COVID-19 in the ageing European population -a SHARE-based analysis, Z Gesundh Wiss, doi:10.1007/s10389-021-01537-7

Ajufo, Rao, Navar, Pandey, Ayers et al., population at increased risk of severe illness from COVID-19, American Journal of Preventive Cardiology

Cdc, COVID-19, people with certain medical conditions

Cdc, Centers for Disease Control and Prevention

Cdc, HIV Nexus clinician resources: HIV treatment and results

Cdc, NHANES about NHANES

Cdc, NHANES tutorials module 3: Weighting

Choi, Park, Lee, Variable effects of underlying diseases on the prognosis of patients with COVID-19, PloS One, doi:10.1371/journal.pone.0254258

Conti, Sellitto, Torsiello, Identification of drug interaction adverse events in patients with COVID-19: A Systematic Review, JAMA Netw Open, doi:10.1001/jamanetworkopen.2022.7970

Dhhs, NHANES survey methods and analytic guidelines

Emami, Javanmardi, Pirbonyeh, Akbari, Prevalence of underlying diseases in hospitalized patients with COVID-19: a systematic review and meta-analysis, Arch Acad Emerg Med

Fda, Coronavirus (COVID-19) Update: FDA authorizes drug combination for treatment of COVID-19

Fda, Drug development and drug interactions | Table of substrates, inhibitors and inducers

Fda, FDA fact sheet for healthcare providers: Emergency use authorization for Lagevrio (molnupiravir) capsules

Fda, FDA fact sheet for healthcare providers: Emergency use authorization for Paxlovid

Gu, Paulose-Ram, Burt, Kit, Prescription cholesterol-lowering medication use in adults aged 40 and over: United States

Hodge, Marra, Marzolini, Drug interactions: a review of the unseen danger of experimental COVID-19 therapies, J Antimicrob Chemother, doi:10.1093/jac/dkaa340

Langford, So, Raybardhan, Leung, Soucy et al., Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis, Clin Microbiol Infect, doi:10.1016/j.cmi.2020.12.018

Low, Setia, Lima, Drug-drug interactions involving antidepressants: focus on desvenlafaxine, Neuropsychiatr Dis Treat, doi:10.2147/NDT.S157708

Marzolini, Kuritzkes, Marra, Boyle, Gibbons et al., Prescribing nirmatrelvir-ritonavir: How to recognize and manage drug-drug interactions, Ann Intern Med, doi:10.7326/M22-0281

Marzolini, Kuritzkes, Marra, Boyle, Gibbons et al., Recommendations for the management of drug-drug interactions between the COVID-19 antiviral nirmatrelvir/ritonavir (Paxlovid) and comedications, Clin Pharmacol Ther, doi:10.1002/cpt.2646

Qato, Alexander, Guadamuz, Lindau, Prescription medication use among children and adolescents in the United States, Pediatrics, doi:10.1542/peds.2018-1042

Rezaee, Pourkarim, Pourtaghi-Anvarian, Entezari-Maleki, Asvadi-Kermani et al., Drug-drug interactions with candidate medications used for COVID-19 treatment: An overview, Pharmacol Res Perspect, doi:10.1002/prp2.705

S K Sr, Kalala, Pm, Sabarathinam, Drug interaction risk between cardioprotective drugs and drugs used in treatment of COVID-19: A evidence-based review from six databases, Diabetes Metab Syndr, doi:10.1016/j.dsx.2022.102451

Seligman, Ferranna, Bloom, Social determinants of mortality from COVID-19: A simulation study using NHANES, PLoS Med, doi:10.1371/journal.pmed.1003490

Shahzadi, Sonmez, Kose, Oktan, Alagoz et al., The prevalence of potential drug-drug interactions in CKD-A retrospective observational study of Cerrahpasa nephrology unit, Medicina, doi:10.3390/medicina58020183

Stader, Khoo, Stoeckle, Back, Hirsch et al., Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effect, J Antimicrob Chemother, doi:10.1093/jac/dkaa253

Talha, Dhamoon, Ritonavir

Van Leeuwen, Brundel, Neef, Van Gelder, Mathijssen et al., Prevalence of potential drug-drug interactions in cancer patients treated with oral anticancer drugs, Br J Cancer, doi:10.1038/bjc.2013.48

Wedemeyer, Blume, Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update, Drug Saf, doi:10.1007/s40264-014-0144-0

Zanger, Schwab, Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation, Pharmacology & Therapeutics

Zhou, Xue, Cc, Yu, Li et al., Clinically important drug interactions potentially involving mechanism-based inhibition of Cytochrome P450 3A4 and the role of therapeutic drug monitoring, Ther Drug Monit

Zhou, Xue, Yu, Li, Wang, Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring, Ther Drug Monit, doi:10.1097/FTD.0b013e31815c16f5

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit